13G Filing: Jafco Sv4 Investment Limited Partnership and Miragen Therapeutics Inc. (NASDAQ:MGEN)

Page 4 of 8 – SEC Filing

CUSIP No. 60463E103 Page 4 of 8



(a) Name of Issuer:
Miragen Therapeutics, Inc.

(b) Address of Issuer’s
Principal Executive Offices: 6200 Lookout Road, Boulder, CO 80301


(a) Name of Person
Filing: This Statement is filed by JAFCO SV4 Investment Limited Partnership (“JAFCO SV4”) and JAFCO Co., Ltd. (“JAFCO
Co., Ltd.”). The foregoing entities are collectively referred to as the “Reporting Persons.” JAFCO Co., Ltd.,
the general partner of JAFCO SV4, may be deemed to have sole power to vote and sole power to dispose of shares of the issuer directly
owned by JAFCO SV4.

(b) Address of Principal
Business Office, or if None, Residence: The address for each of the Reporting Persons is: Otemachi First Square West Tower 11F,
1-5-1, Otemachi Chiyoda-Ku Tokyo, Japan 100-0004

(c) Citizenship: The
citizenship of each of the Reporting Persons is Japan

(d) Title of Class
of Securities: Common Stock

(e) CUSIP Number:

TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable

  (a) [_] Broker or dealer registered under Section 15 of the Act  (15 U.S.C. 78o).
  (b) [_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).   
  (c) [_] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).   
  (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
  (e) [_] An investment adviser in accordance with  ss.240.13d-1(b)(1)(ii)(E);   
  (f) [_] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);   
  (g) [_] A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);   
  (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);   
  (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);   
  (j) [_] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

Follow Viridian Therapeutics Inc. (NASDAQ:VRDN)